Log In
BCIQ
Print this Print this
 

MEDI3902

Also known as: MEDI-3902

  Manage Alerts
Collapse Summary General Information
Company AstraZeneca plc
DescriptionBispecific mAb that targets P. aeruginosa type III secretion protein PcrV and Psl exopolysaccharide
Molecular Target P. aeruginosa type III secretion protein PcrV ; P. aeruginosa Psl exopolysaccharide
Mechanism of ActionBispecific antibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPhase II
Standard IndicationPneumonia
Indication DetailsPrevent nosocomial pneumonia caused by Pseudomonas aeruginosa
Regulatory Designation U.S. - Fast Track (Prevent nosocomial pneumonia caused by Pseudomonas aeruginosa)
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today